This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Genesis Healthcare, Inc. (GEN) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Genesis Healthcare, Inc. (GEN).
New Strong Buy Stocks for September 16th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Is Genesis Healthcare (GEN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GEN) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for September 5th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 5th
New Strong Buy Stocks for September 4th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Genesis Healthcare (GEN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Genesis Healthcare (GEN) delivered earnings and revenue surprises of 61.54% and -0.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Genesis Healthcare (GEN) This Season?
by Zacks Equity Research
Genesis Healthcare's (GEN) Q2 earnings should benefit from a stable census and reimbursement environment, effective cost management, improvement in therapy and staffing businesses.
Will Genesis Healthcare (GEN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Genesis Healthcare (GEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Genesis Healthcare (GEN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Genesis Healthcare (GEN) closed at $1.16, marking a +0.87% move from the previous day.
Zacks.com featured highlights include: Guess, Party City, Shoe Carnival, Genesis and Restoration Robotics
by Zacks Equity Research
Zacks.com featured highlights include: Guess, Party City, Shoe Carnival, Genesis and Restoration Robotics
Is Genesis Healthcare (GEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GEN) Outperforming Other Medical Stocks This Year?
Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
4 Nursing Homes Stocks to Gain From an Aging U.S. Population
by Sapna Bagaria
Changing demography in the United States should continue to favor the companies in the nursing home industry.
Ensign Group (ENSG) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Ensign Group (ENSG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Fast-Aging Global Population a Boon for These 5 Stocks
by Sanghamitra Saha
The UN report says that the number of persons aged 80 or over is projected to triple by 2050. These top-ranked stocks should benefit from fast-aging global population.
Fed and Trade Pull Down U.S. Treasury Yields: 5 Safe Picks
by Nalak Das
As investors' appetite for risky assets like equities weakened to a large extent, flow of funds started shifting from equities to bond markets.
New Strong Buy Stocks for June 21st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Acadia Healthcare Up 32% YTD: What's Driving the Rally?
by Zacks Equity Research
Acadia Healthcare's strong presence in the growing behavioral healthcare business with solid fundamentals has helped the stock to rally.
Nursing Industry Outlook Bright on Low-Cost Care & Demography
by Sapna Bagaria
An aging baby boomer population, need for low-cost care facilities and consolidation should aid the growth of the nursing industry.
Ensign Group (ENSG): Attractive Stock to Own
by Zacks Equity Research
Strong fundamentals along with changing U.S. demography are expected to favor The Ensign Group (ENSG).
New Strong Buy Stocks for May 23rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Ensign Group (ENSG) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Ensign Group (ENSG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Will Genesis Healthcare (GEN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Genesis Healthcare (GEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ensign Up More Than 90% in a Year: Will the Rally Continue?
by Zacks Equity Research
Strong fundamentals along with industry's growth drivers are ensuring growth at Ensign (ENSG)
Will Genesis Healthcare (GEN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Genesis Healthcare (GEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.